BenchSci is a global leader in machine learning applications for novel medicine development.
BenchSci's mission is to exponentially increase the speed and quality of life-saving research.
BenchSci was founded in 2015 by Tom Leung, David Q. Chen, Elvis Wianda, and Liran Belenzon. The company is headquartered in Toronto, Ontario, Canada.
BenchSci’s proprietary machine learning models—trained to understand experiments like a Ph.D. scientist—extract critical insights from published scientific data sources and pharmaceutical organizations' internal databases.
BenchSci leverages over 100 proprietary machine learning models to empower 49,000 scientists globally to optimize their experiment designs and hence research productivity.
BenchSci is evolving its technology to provide a comprehensive platform with capabilities that help leading pharmaceutical companies solve their biggest R&D challenges. BenchSci accelerates research in 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide.
BenchSci is backed by F-Prime Capital, Inovia Capital, TCV, Gradient Ventures, Northleaf Capital Partners, Golden Ventures, and others. The company raised CA $63M ($50M) in Series C round on Jan 24, 2022. This brings BenchSci's total funding to $94.6M to date.